AnaptysBio had its Relative Strength (RS) Rating upgraded from 61 to 78 Tuesday — a welcome improvement, but still below the 80 or higher score you prefer to see.
Can You Really Time The Stock Market?
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if AnaptysBio can continue to show renewed price strength and clear that threshold.
While AnaptysBio is not near an ideal entry right now, see if it manages to form and break out of a proper base.
The company reported 0% EPS growth last quarter. Sales gains came in at 287%.
AnaptysBio holds the No. 117 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
